180 related articles for article (PubMed ID: 8404092)
1. Phenotypes and lymphokine-activated killer activity of pleural cavity lymphocytes of lung cancer patients without malignant effusion.
Takahashi K; Sone S; Kimura S; Ogura T; Monden Y
Chest; 1993 Jun; 103(6):1732-8. PubMed ID: 8404092
[TBL] [Abstract][Full Text] [Related]
2. Lymphokine-activated killer induction and its regulation by macrophages in malignant pleural effusions.
Yanagawa H; Sone S; Nii A; Fukuta K; Nakanishi M; Maeda K; Honda M; Ogura T
Jpn J Cancer Res; 1989 Dec; 80(12):1220-7. PubMed ID: 2516849
[TBL] [Abstract][Full Text] [Related]
3. Granulocyte-macrophage colony-stimulating factor augments lymphokine-activated killer activity from pleural cavity mononuclear cells of lung cancer patients without malignant effusion.
Takahashi K; Sone S; Saito S; Kamamura Y; Uyama T; Ogura T; Monden Y
Jpn J Cancer Res; 1995 Sep; 86(9):861-6. PubMed ID: 7591964
[TBL] [Abstract][Full Text] [Related]
4. [The cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells].
Guo Y; Xing Z
Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):80-2, 127. PubMed ID: 7553955
[TBL] [Abstract][Full Text] [Related]
5. Granulocyte/macrophage-colony-stimulating factor augments lymphokine-activated killer activity from lymphocytes via macrophages in lung cancer patients.
Takahashi K; Saito S; Kamamura Y; Katakawa M; Monden Y
Cancer Immunol Immunother; 2000 Dec; 49(10):537-43. PubMed ID: 11129324
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-2-inducible killer activity and its regulation by blood monocytes from autologous lymphocytes of lung cancer patients.
Sone S; Kunishige E; Fawzy F; Yanagawa H; Nii A; Maeda K; Atagi S; Heike Y; Nishioka Y; Mizuno K
Jpn J Cancer Res; 1991 Jun; 82(6):716-23. PubMed ID: 1649813
[TBL] [Abstract][Full Text] [Related]
7. A study of the cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells.
Guo YS; Xing ZL
Chin Med J (Engl); 1994 Dec; 107(12):903-5. PubMed ID: 7882727
[TBL] [Abstract][Full Text] [Related]
8. Gamma-interferon enhances the cytotoxic activity of interleukin-2-induced peripheral blood lymphocyte (LAK) cells, tumor infiltrating lymphocytes (TIL), and effusion associated lymphocytes.
Papamichail M; Baxevanis CN
J Chemother; 1992 Dec; 4(6):387-93. PubMed ID: 1287141
[TBL] [Abstract][Full Text] [Related]
9. Lymphokine-activated killer cytotoxicity and lymphocyte subpopulations in patients with acute leukemia.
Parrado A; Casares S; RodrÃguez-Fernández JM
Leuk Res; 1994 Nov; 18(11):815-22. PubMed ID: 7526078
[TBL] [Abstract][Full Text] [Related]
10. OK-432 develops CTL and LAK activity in mononuclear cells from regional lymph nodes of lung cancer patients.
Takahashi K; Harauchi D; Kimura S; Saito S; Monden Y
Int J Immunopharmacol; 1998 Aug; 20(8):375-88. PubMed ID: 9778099
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effect of Nocardia rubra cell wall skeleton and recombinant interleukin 2 for in vivo induction of lymphokine-activated killer cells.
Miyazaki K; Yasumoto K; Yano T; Matsuzaki G; Sugimachi K; Nomoto K
Cancer Res; 1991 Oct; 51(19):5261-5. PubMed ID: 1833049
[TBL] [Abstract][Full Text] [Related]
12. Cross regulation by IL-10 and IL-2/IL-12 of the helper T cells and the cytolytic activity of lymphocytes from malignant effusions of lung cancer patients.
Chen YM; Yang WK; Ting CC; Tsai WY; Yang DM; Whang-Peng J; Perng RP
Chest; 1997 Oct; 112(4):960-6. PubMed ID: 9377959
[TBL] [Abstract][Full Text] [Related]
13. Long-term cultures of human peripheral blood lymphocytes with recombinant human interleukin-2 generate a population of virtually pure CD3+ CD16- CD56- large granular lymphocyte LAK cells.
Roussel E; Gerrard JM; Greenberg AH
Clin Exp Immunol; 1990 Nov; 82(2):416-21. PubMed ID: 1700746
[TBL] [Abstract][Full Text] [Related]
14. Augmented human-tumor-cytolytic activity of peripheral blood lymphocytes and cells from a mixed lymphocyte/tumor culture activated by interleukin-12 plus interleukin-2, and the phenotypic characterization of the cells in patients with advanced carcinoma.
Koyama S
J Cancer Res Clin Oncol; 1997; 123(9):478-84. PubMed ID: 9341896
[TBL] [Abstract][Full Text] [Related]
15. Lymphokine-activated killer (LAK) cell activity in tumor-infiltrating lymphocytes from non-small cell lung cancer.
Pisani RJ; Krco CJ; Wold LE; McKean DJ
Am J Clin Pathol; 1989 Oct; 92(4):435-46. PubMed ID: 2552792
[TBL] [Abstract][Full Text] [Related]
16. The intrapleural administration of recombinant interleukin-2 (rIL-2) to patients with malignant pleural effusion: clinical trials.
Suzuki H; Abo S; Kitamura M; Hashimoto M; Izumi K
Surg Today; 1993; 23(12):1053-9. PubMed ID: 8118118
[TBL] [Abstract][Full Text] [Related]
17. Combination of lymphokine-activated killer cells and interleukin-2 in treating metastatic renal cell carcinoma.
Fujioka T; Nomura K; Hasegawa M; Ishikura K; Kubo T
Br J Urol; 1994 Jan; 73(1):23-31. PubMed ID: 8298895
[TBL] [Abstract][Full Text] [Related]
18. The characterization of peritoneal and pleural exudate cells from malignant effusions.
Oka M; Yoshino S; Hazama S; Shimoda K; Suzuki T
Surg Today; 1993; 23(6):500-3. PubMed ID: 8102920
[TBL] [Abstract][Full Text] [Related]
19. Generation of killer activity by interleukin-12 of mononuclear cells in malignant pleural effusions due to lung cancer.
Hiramatsu K; Yanagawa H; Haku T; Sone S
Cancer Immunol Immunother; 1998 Mar; 46(1):1-6. PubMed ID: 9520285
[TBL] [Abstract][Full Text] [Related]
20. Effector function of lymphokine-activated killer cells and cytotoxic T lymphocytes in ovarian epithelial carcinoma.
Lentz SS; Kovach JS; McKean DJ; Wieand HS; Podratz KC
Gynecol Oncol; 1990 Aug; 38(2):191-6. PubMed ID: 2387535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]